Sarepta Therapeutics (SRPT): Needham & Company Highlights 2 Significant Positive Implications from Dolodiresen Data

Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrust

SunTrust Robinson Humphrey analyst Edward Nash reiterated a Buy rating and $56 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive muscle biopsy results from the Phase I/II 4053-101 study that evaluated golodirsen (SRP-4053) for the treatment of DMD patients... More

Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William Blair

William Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data from its ongoing European Phase I/II study for DMD patients amenable to skipping exon 53 with golodirsen (SRP-4053).

Lugo notes all... More

UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper Jaffray

(Updated - September 6, 2017 11:00 AM EDT)

(updated to add analyst comment)

Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $55.00 (from $50.00) while maintaining a Overweight rating.

Analyst Edward Tenthoff notes the positive Exon 53 data. The analyst further comments... More

Sarepta (SRPT) SRP-4053 Data Strengthen Case for Exon Expansion Approach - Baird; Reit. OP, $101 PT

Baird analyst Brian Skorney reiterated an Outperform rating and $101 price target on Sarepta Therapeutics (NASDAQ: SRPT) following positive European Phase 1/2 study of SRP-4053.

Skorney said this strengthens the case for Sarepta's approach to exon expansion.

"With dystrophin expression exceeding that... More

Sarepta Therapeutics (SRPT) Phase 1/2 Study of Golodirsen in DMD Hits Statistical Significance on all Primary and Secondary Endpoints

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today announced muscle biopsy results from its 4053-101 study, a Phase 1/2 first-in-human study conducted in Europe to assess the safety, tolerability, pharmacokinetics, and efficacy of golodirsen in 25 boys with confirmed deletions of the DMD gene amenable to skipping exon 53. The study comprised two parts. In Part 1, 12 patients were randomized to receive a dose titration of golodirsen (8 patients) or placebo (4 patients). At the end of Part 1 (dose titration), all 12 patients continued on golodirsen and an additional 13 patients started golodirsen (Part 2). In Part 2, all 25 patients were treated for an... More